A61K 49/101
The carrier being a complex-forming compound able to form mri-active complexes with
Official title: {the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals}
A61K49/101 (The carrier being a complex-forming compound able to form mri-active complexes with) appears on 460 US grants and 595 published applications in this corpus.
Search patents in A61K- Granted patents
- 460
- Published applications
- 595
- Assignees
- 295
- Inventors
- 1,262
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 12 | 0 |
| 1996 | 15 | 0 |
| 1997 | 16 | 0 |
| 1998 | 7 | 0 |
| 1999 | 11 | 0 |
| 2000 | 11 | 0 |
| 2001 | 4 | 1 |
| 2002 | 6 | 10 |
| 2003 | 5 | 13 |
| 2004 | 7 | 19 |
| 2005 | 8 | 17 |
| 2006 | 7 | 16 |
| 2007 | 6 | 16 |
| 2008 | 7 | 13 |
| 2009 | 4 | 16 |
| 2010 | 6 | 16 |
| 2011 | 6 | 22 |
| 2012 | 11 | 15 |
| 2013 | 11 | 17 |
| 2014 | 18 | 30 |
| 2015 | 10 | 23 |
| 2016 | 16 | 36 |
| 2017 | 24 | 36 |
| 2018 | 19 | 24 |
| 2019 | 27 | 35 |
| 2020 | 30 | 50 |
| 2021 | 32 | 34 |
| 2022 | 30 | 36 |
| 2023 | 20 | 34 |
| 2024 | 17 | 27 |
| 2025 | 23 | 26 |
| 2026 | 17 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Manganese-enhanced magnetic resonance imaging29 Sep 2026US 12,745,921 B2Ic Targets AS
- Iron complexes and salts thereof as contrast agents for MRI25 Aug 2026US 12,715,891 B2Bracco Imaging S.P.A.
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- Pharmaceutical compositions of Gd-based contrast agents21 Jul 2026US 12,685,788 B2Bracco Imaging S.P.A.
- Nanosystems as selective vehicles19 May 2026US 12,629,427 B2Servizo Galego De SAúDe FundacióN Instituto De InvestigacióN Sanitaria De Santiago De Compostela (Fidis)
- Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents8 Oct 2026US 2026/0306634 A1Wisconsin Alumni Research Foundation
- Pharmaceutical compositions of gd-based contrast agents8 Oct 2026US 2026/0306679 A1Bracco Imaging S.P.A.
- Pet/mri contrast agents for in vivo quantification of extracellular acidification13 Aug 2026US 2026/0232848 A1Eberhard Karls Universität Tübingen Medizinische Fakultät Körperschaft des öffentlichen Rechts
- Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals6 Aug 2026US 2026/0226078 A1Clarity Pharmaceuticals Ltd
- Imaging agents for detecting cd206+ macrophages2 Jul 2026US 2026/0183432 A1The General Hospital Corporation
Most cited
By later US patents
- Diagnostic media413US 4,647,447 ASchering Corporation · 1987
- Method of expanded porphyrin-oligonucleotide conjugate synthesis325US 5,565,552 ABoard of Regents, Univ. of Texas Sys. · 1996
- Texaphyrin-oligonucleotide conjugates308US 5,587,371 ABoard of Trustees, Univ. of TX Sys. · 1996
- Texaphyrin metal complexes having improved functionalization254US 5,599,923 ABoard of Regents, University of TX · 1997
- Texaphyrin compounds having improved functionalization233US 5,599,928 ABoard of Regents, The University of Texas System · 1997